


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 20, 2003 (use as many sheets as necessary)				Complete if Known	
Sheet	1	of	3	Application Number	08/632,533
				Filing Date	04/12/1996
				First Named Inventor	Daniel J. Drucker
				Group Art Unit	1642
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	016777-0528



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
84	A1	5,912,229		THIM et al.	06/15/99

RECEIVED
SEARCH CENTER
MAR 21 2003

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴	Kind Code ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
84	A2	EP	612,531		08/31/94

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
84	A3	BARRAGAN, et al., Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1 (7-36) amide in rats. <i>American Journal of Physiology</i> . 266 (3 Pt 1), pE459-66, March 1994.			
84	A4	BLOOM, et al., Gut Hormones in adaptation. <i>Gut</i> . 28, S1, pp. 31-35, 1987.			
84	A5	BRUBAKER, et al., Regulation of Intestinal Proglucagon-Derived Peptide Secretion by Intestinal Regulatory Peptides. <i>Endocrinology</i> . Vol. 128, No. 6, pp. 3175-3182, 1991.			
84	A6	BUHL, et al., Naturally Occurring Products of Proglucagon 111-160 in the Porcine and Human Small Intestine. <i>The Journal of Biological Chemistry</i> . Vol. 263, No. 18, pp. 8621-8624, Issue of June 25, 1988.			
84	A7	CALVO, et al., Structural characterization by affinity cross-linking of glucagon-like peptide-1 (7-36) amide receptor in rat brain. <i>J. Neurochem.</i> 64(1), pp. 299-306, January 1995.			
84	A8	CHEESEMAN, et al., The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal basolateral membrane hexose transport. <i>The American Physiological Society</i> . APSracts 3:0071G, April 16, 1996. (Abstract only)			
84	A9	DRUCKER, et al., <i>Pancreas</i> . 1990, 5(4):484			
84	A10	EHRLICH, et al., Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. <i>American Journal of Physiology</i> . pp. E662-E671, 1994.			

Examiner Signature	84	Date Considered	12/29/04
--------------------	----	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (W-PO Standard ST, 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 20, 2003 (use as many sheets as necessary)			Application Number 08/632,533 Filing Date 04/12/1996 First Named Inventor Daniel J. Drucker Group Art Unit 1642 Examiner Name Not Yet Assigned		
Sheet	2	of	3	Attorney Docket Number	016777-0528

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
DT	A11	GEORGE, et al., Molecular forms of glucagon-like peptides in man. <i>FEBS Letters</i> . Vol. 192, No. 2, pp. 275-278, November 1985.	
DT	A12	HOSEIN, et al., Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase. <i>FEBS Letters</i> . Vol. 178, No. 1, pp. 83-86, December 1984.	
DT	A13	IRWIN, et al., Trout and Chicken Proglucagon: Alternative Splicing Generates mRNA Transcripts Encoding Glucagon-Like Peptide 2. <i>Molecular Endocrinology</i> . 9:267-277, 1995.	
DT	A14	LEE, et al., Glucagon Gene 5'-Flanking Sequences Direct Expression of Simian Virus 40 Large T Antigen to the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice. <i>The Journal of Biological Chemistry</i> . Vol. 267, No. 15, pp. 10706-10708, May 25, 1992.	
DT	A15	LUND, et al., Regulation of Intestinal Glucagon Gene Expression during Adaptive Growth of Small Intestine. <i>Digestion</i> . 54:371-373, 1993.	
DT	A16	MOJSOV, et al., Preproglucagon Gene Expression in Pancreas and Intestine Diversifies at the Level of Post-translational Processing. <i>The Journal of Biological Chemistry</i> . Vol. 261, No. 25, pp. 11880-11889, September 5, 1986.	
DT	A17	MOMMSEN, et al., Glucagon-like peptides activate hepatic gluconeogenesis. <i>FEBS Letters</i> . Vol. 219, No. 1, pp. 227-232, July 1987.	
DT	A18	NISHI, et al., <i>Mol. Endocrinol.</i> , 1990, 4:1192-8.	
DT	A19	ORSKOV, et al., Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine. <i>FEBS Letters</i> . 247(2), pp. 193-196, April 24, 1989.	

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

Examiner
Signature



Date
Considered 12/29/04

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 20, 2003 (use as many sheets as necessary)				Application Number	08/632,533
Sheet	3	of	3	Filing Date	04/12/1996
				First Named Inventor	Daniel J. Drucker
				Group Art Unit	1642
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	016777-0528



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
DL	A20	ORSKOV, et al., Pancreatic and intestinal processing of proglucagon in man. <i>Diabetologia</i> . 30:874-881, 1987.			T ⁶
glk	A21	ORSKOV, et al., Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). <i>Scand. J. Clin. Lab. Invest.</i> 47(2), pp. 165-174, April 1987.			
DA	A22	ORSKOV, et al., Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene. Are Secreted Separately from Pig Small Intestine but Not Pancreas. <i>Endocrinology</i> . Vol. 119, No. 4, pp. 1467-1475, 1986.			
SA	A23	RUIZ-GRAND, et al., Renal catabolism of human glucagon-like peptides 1 and 2. <i>Can. J. Physiol. Pharmacol.</i> 68 (12), pp. 1568-1573, Dec. 1990.			
gk	A24	SHENNAN, et al., Proglucagon expression, post-translational processing and secretion in SV40-transformed islet cells. <i>Molecular and Cellular Endocrinology</i> . 67(1989), pp. 93-99.			
DA	A25	WATANABE, et al., Trophic Effect of Glucagon-(1-21)-Peptide on the Isolated Rat Ileal Mucosal Cells. <i>Biochemical and Biophysical Research Communications</i> . Vol. 152, No.3, pp. 1038-1044, May 16, 1988.			

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

Examiner Signature	DA	Date Considered	12-29-04
--------------------	----	-----------------	----------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

²Unique citation designation number ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible ⁷Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231

002.986220.1